The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC)

The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) is the only research consortium dedicated to evaluating the real-world safety and effectiveness of biologics, including biosimilars.

BBCIC is a non-profit research consortium that monitors the safety and effectiveness of biosimilars and novel biologics and provides the assurance needed to determine which medications deliver the best health outcomes.

AMCP established BBCIC in 2015 to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars, and other related products. The BBCIC’s mission is to provide research services that:

  • Address important questions about the use, impact, safety, and clinical effectiveness of biologics including biosimilars on human health
  • Increase the rigor and credibility of real-world evidence
  • Provide access to a large population for epidemiologic studies and health services research
  • Improve the efficiency and cost-effectiveness of post-marketed observational studies
  • Develop standard approaches to common data needs and address gaps in tools and methods

Harvard Pilgrim Health Care Institute provides coordination and analytical support for BBCIC, with Jeffrey Brown, PhD serving as project lead. Other key team members include Sarah Malek, MPPA; James Marshall, MPH; Aaron Mendelsohn, PhD, MPH: and Young Hee Nam, PhD.

Related Publications

Related Links

Principal Investigator

Jeffrey Brown, PhD